Results for the substance niraparib abiraterone

The combination of niraparib and abiraterone is being investigated for its potential in treating advanced prostate cancer. Niraparib, a PARP inhibitor, and abiraterone, an androgen synthesis inhibitor, work synergistically to reduce disease progression. This combination is particularly of interest for patients with genetic mutations affecting DNA repair.

These medications are administered orally, with doses adjusted based on the patient's condition and treatment tolerance. Side effects may include fatigue, nausea, high blood pressure, and electrolyte imbalances. Careful monitoring is essential to prevent complications.

This combination is contraindicated in patients with severe liver impairment or hypersensitivity to any of the components. Additionally, use during pregnancy is strictly prohibited due to risks to the fetus.

Although still under investigation, the niraparib and abiraterone combination offers hope for patients with advanced prostate cancer, especially those with limited therapeutic options. It is important that treatment is administered under the supervision of a specialist.